• What is diabetic retinopathy?
• What is diabetic nephropathy?
• Who is at risk for diabetic retinopathy and diabetic nephropathy?
• What are the symptoms?
• How is diabetic retinopathy treated?
• What research has been done?
• How does Nepretin work?
• How do I take Nepretin and for how long?
• What adverse effects can I expect while taking Nepretin?
  

A: Diabetic retinopathy is a potentially blinding complication of diabetes that damages the eye’s retina. It affects over 4.1 million Americans diagnosed with diabetes. Diabetic retinopathy occurs when the explosion of free radicals causes clogging and damages the tiny blood vessels in the retina. It is a progressive disease, and eventually, if enough of the retina is destroyed total blindness may result.

A: Diabetic nephropathy is deterioration of the kidneys caused by proliferated growth and subsequent bursting of the tiny blood vessels in the kidneys.

A: All people with diabetes, both Type I and Type II, are at risk. Diabetic retinopathy affects over 4.1 million Americans at any given time. Approximately 10% of diabetics, or 1.6 million people in the United States, suffer from diabetic nephropathy.

A: Diabetic retinopathy often has no early warning signs. At some point, however, one may have macular edema (blood vessels leaking fluid onto the macula, the part of the retina that allows us to see detail). It blurs vision, making it difficult to do things like read and drive. In its early stages, diabetic nephropathy has no clinical signs or symptoms.

A: Currently the only treatments for diabetic retinopathy involve the invasive treatment of surgery. Surgery is not a cure and it may need to be repeated more than once. Nutrient Synergy provides all-natural diabetes supplements designed to slow, stop or even reverse diabetic retinopathy.

A: In recent years there has been a surge of interest in the role of antioxidants in health and disease. An article in Diabetes Self-Management (March/April 1997) noted: “There is preliminary research in animals that suggests that antioxidants may help slow the progression of diabetic retinopathy.” More recently a lengthy, 100-patient, double-blind, randomized clinical trial was completed by LiForce International, Inc., at a major medical university. The trial studied the effects of Nepretin, a proprietary formulation consisting of a complex blend of pharmaceutical grade antioxidants and micronutrients, in slowing, stopping, or reversing the symptoms of diabetic retinopathy and nephropathy in human patients with Type I diabetes.

A: Nepretin has been designed to slow the progression of diabetic retinopathy and diabetic nephropathy and as a preventive for anyone at risk. The formula combines select nutrients that are beneficial with a broad spectrum of antioxidants and bioflavonoids that help control the effects of oxygen-derived free radicals on related tissues. Substantial evidence from LiForce International clinical trial supports the concept that oxygen metabolites can modify the structure and function of various cell and tissue types. These changes appear to result in conditions such as cardiovascular disease, kidney nephropathy, and retinopathy.

A: Three capsules of Nepretin should be taken twice daily, preferably with food. Based on the clinical trial, Nepretin should be taken for up to 24 months before experiencing measurable results. Progression of diabetic retinopathy and diabetic nephropathy will likely reoccur upon discontinuation of Nepretin.

A: Although in clinical trial, patients taking Nepretin displayed no contraindications, it is recommended that you consult with your health professional if you experience any adverse effects.